Overall, payers will need to take a collaborative and cooperative approach across provider, PBM, manufacturer and third-party condition management program stakeholders to effectively expand coverage to members
Several factors influence the final cost: Type of medication: Daily liraglutide injections, weekly semaglutide injections, dual GLP-1/GIP tirzepatide injections, and oral semaglutide tablets are priced differently
In human tests, an oral dosage of 250 g/kg body weight resulted in a reduction of two injections per day [34]
[For example,] a patient whose main issue is inflammation might benefit more from the anti-inflammatory effect of the drug than a patient whose Crohn's disease has led to strictures, [or] a narrowing of the intestine. The Takeaway GLP-1s decrease inflammation throughout the body, and may improve Crohns disease outcomes
And it kind of became fun that way. The first GLP-1-based drug has an unusual origin story